Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Want to see NVCT full AI Analyst Report?
Top Page
Nuvectis Pharma
(NASDAQ:NVCT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$10.50
▲(17.98% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily weighed down by weak financial performance (pre-revenue, larger losses, and meaningful cash burn), partially offset by a debt-free balance sheet. Technicals are supportive due to a strong uptrend, but overbought conditions raise near-term downside risk. Valuation provides limited support because profitability is negative and no dividend is indicated.
Positive Factors
Debt-free balance sheet
Zero total debt materially reduces insolvency and fixed-cost risk for a clinical-stage biotech. Low leverage preserves flexibility to pursue equity financings, partnerships, or milestone-based deals without immediate interest burdens, supporting continuity of development programs.
Negative Factors
Pre-revenue status
Being pre-revenue means the firm lacks commercial cash inflows and depends entirely on financing or partnerships to fund R&D. This structural reliance increases dilution and execution risk, making long-term sustainability contingent on clinical success or deal-making within the financing horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero total debt materially reduces insolvency and fixed-cost risk for a clinical-stage biotech. Low leverage preserves flexibility to pursue equity financings, partnerships, or milestone-based deals without immediate interest burdens, supporting continuity of development programs.
Read all positive factors
Nuvectis Pharma (NVCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$274.54M
Dividend YieldN/A
Average Volume (3M)89.48K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue GrowthN/A
EPS Growth-16.88%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.31
Shares Outstanding26,525,534
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.82
Forecast
1Y Price Target
$13.50Price Target Upside51.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Nuvectis Pharma Business Overview & Revenue Model
Company Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment...
How the Company Makes Money
As a clinical-stage biotechnology company, Nuvectis Pharma does not have publicly available information indicating recurring revenue from approved product sales. Its funding and cash inflows are therefore primarily associated with capital-raising ...
Nuvectis Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -28.27M | -27.57M | -19.00M | -22.90M | -19.23M | -12.89M |
| Net Income | -27.16M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
Balance Sheet | ||||||
| Total Assets | 25.40M | 31.71M | 18.61M | 19.18M | 20.41M | 6.66M |
| Cash, Cash Equivalents and Short-Term Investments | 25.13M | 31.63M | 18.53M | 19.13M | 19.99M | 5.74M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 11.18M | 13.30M | 8.89M | 6.98M | 6.19M | 17.66M |
| Stockholders Equity | 14.22M | 18.41M | 9.71M | 12.20M | 14.22M | -11.01M |
Cash Flow | ||||||
| Free Cash Flow | -18.35M | -16.01M | -12.25M | -15.95M | -13.56M | -9.50M |
| Operating Cash Flow | -18.35M | -16.01M | -12.25M | -15.95M | -13.56M | -9.50M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 13.61M | 29.11M | 11.65M | 15.09M | 27.81M | 15.25M |
Nuvectis Pharma Technical Analysis
Positive
8.90
Price Trends
9.03
Positive
8.83
Positive
7.63
Positive
Market Momentum
0.55
Positive
52.89
Neutral
17.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCT, the sentiment is Positive. The current price of 8.9 is below the 20-day moving average (MA) of 10.19, below the 50-day MA of 9.03, and above the 200-day MA of 7.63, indicating a bullish trend. The MACD of 0.55 indicates Positive momentum. The RSI at 52.89 is Neutral, neither overbought nor oversold. The STOCH value of 17.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVCT.
Nuvectis Pharma Risk Analysis
Nuvectis Pharma disclosed 50 risk factors in its most recent earnings report. Nuvectis Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuvectis Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $216.78M | -1.41 | -30.90% | ― | ― | 10.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $124.18M | -1.00 | -135.60% | ― | ― | 17.43% | |
49 Neutral | $274.54M | -7.48 | -147.78% | ― | ― | -16.88% | |
44 Neutral | $162.64M | -1.77 | -49.86% | ― | -100.00% | 0.03% | |
41 Neutral | $243.12M | -1.97 | -137.99% | ― | 1033.89% | 36.35% |
* Healthcare Sector Average
NVCT
Nuvectis Pharma
10.35
0.69
7.14%
NKTX
Nkarta
3.03
1.29
74.14%
OBIO
Orchestra BioMed Holdings
4.06
1.24
43.97%
GLSI
Greenwich LifeSciences
27.65
17.67
177.05%
MOLN
Molecular Partners
4.18
0.12
2.96%
PYXS
Pyxis Oncology
1.96
0.72
58.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.